Drug Trial Radar · NCT00152464
Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)
Last checked: Nov 20, 2026Latest source record: Jan 22, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
514
Actual
Start
Mar 20, 2002
Primary completion
Mar 15, 2006
Study completion Mar 15, 2006
Sponsor
- Lead sponsor
- UCB Pharma SAUCB
- Sponsor type
- Industry
- First posted
- Sep 9, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 months, up to 24 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Early Prevention of Asthma in Atopic Children (EPAAC™). 24 months study to evaluate the efficacy and safety of levocetirizine (LCTZ) in preventing the onset of asthma in 12 to 24 months old children.
Conditions
- Dermatitis, Atopic
Interventions
PlaceboDrug
Pharmaceutical form: Oral drops Route of administration: Oral use
LevocetirizineDrug
Pharmaceutical form: Oral drops Concentration: 5 mg/ml Route of administration: Oral use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Onset of Asthma During the Treatment PeriodTime frame: During the treatment period (18 months)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.